Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

"Pathogen Eradication" and "Emerging Pathogens": Difficult Definitions in Cystic Fibrosis.

Peter H Gilligan1,2, Damian G Downey3,4, J Stuart Elborn4,5,6

  • 1Pathology and Laboratory Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina, USA Peter.Gilligan@unchealth.unc.edu.

Journal of Clinical Microbiology
|June 8, 2018
PubMed

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Microbiome-Targeted Antibiotics Provide No Additional Microbiologic or Inflammatory Benefit during Cystic Fibrosis Pulmonary Exacerbations: Results from the CFMATTERS Trial.

American journal of respiratory and critical care medicine·2026
Same author

Mucoactive agents in bronchiectasis: a systematic review and meta-analysis.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Safety and antimicrobial efficacy of CSL787, a novel nebulized IgG therapy, in patients with bronchiectasis: results from a randomized phase 1 trial.

American journal of respiratory and critical care medicine·2026
Same author

Contributors to the heterogeneity of response to CFTR modulators.

The Lancet. Respiratory medicine·2026
Same author

Hypertonic Saline or Carbocisteine in Bronchiectasis. Reply.

The New England journal of medicine·2026
Same author

Determinants of early Elexacaftor-Tezacaftor-Ivacaftor use in adults with cystic fibrosis and preserved lung function: insights from a European multicenter survey.

Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society·2026
Summary
This summary is machine-generated.

Treatments for cystic fibrosis (CF) airway infections aim to eradicate pathogens and suppress microbial growth. New therapies may alter airway microbial communities, necessitating monitoring for pathogen emergence and clearance in CF patients.

Area of Science:

  • Pulmonary Medicine
  • Microbiology
  • Genetics

Background:

  • Infection is a frequent complication in cystic fibrosis (CF) airway disease.
  • Current CF treatments involve pathogen eradication and chronic antibiotic use.
  • Emerging therapies target CFTR function, inflammation, and airway clearance, potentially impacting airway microbes.

Purpose of the Study:

  • To define the timing of key pathogen eradication in CF patients.
  • To identify the emergence of new pathogens due to novel therapies.
  • To understand the impact of new CF treatments on airway microbial communities.

Main Methods:

  • Monitoring pathogen presence and absence in CF airways.
  • Analyzing changes in microbial communities over time.
Keywords:
Mycobacterium abscessusPseudomonas aeruginosaStaphylococcus aureuschronic infectioncystic fibrosisemerging pathogeneradication

Related Experiment Videos

  • Correlating therapeutic interventions with microbial shifts.

    • Main Results:

    • Data on pathogen eradication timing is crucial.
    • Understanding pathogen emergence linked to new therapies is essential.
    • Novel treatments may influence the airway microbiome in CF.

    Conclusions:

    • Close monitoring of microbial dynamics is vital during new CF treatment regimens.
    • Defining pathogen clearance and emergence windows is critical for optimizing CF care.
    • Further research is needed to fully elucidate the impact of novel CF therapies on airway infections.